[Therapeutic effect of etofyllinclofibrate in disordered lipid and uric acid metabolism].
D000328:Adult; D000368:Aged; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL; D002986:Clinical Trials as Topic; D002994:Clofibrate / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006951:Hyperlipoproteinemias / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008075:Lipoproteins, HDL / Q000097:blood; D008297:Male; D008659:Metabolic Diseases / Q000188:drug therapy; D008875:Middle Aged; D014527:Uric Acid / Q000097:blood / Q000378:metabolism
D008076:Cholesterol, HDL; D000960:Hypolipidemic Agents; D008075:Lipoproteins, HDL; C028764:etofylline clofibrate; D014527:Uric Acid; D002784:Cholesterol; D002994:Clofibrate
Der therapeutische Effekt von Etofyllinclofibrat beim gestörten Lipid- und Harnsäurestoffwechsel.